A serpin-induced extensive proteolytic susceptibility of urokinase-type plasminogen activator implicates distortion of the proteinase substrate-binding pocket and oxyanion hole in the serpin inhibitory mechanism

European Journal of Biochemistry

Volumn 268, Issue 3, 2001, Pages 673-685

  Egelund, Rikke ^a   Petersen, Torben E ^a   Andreasen, Peter A ^a  

^a AARHUS UNIVERSITY   (Denmark)

Author keywords

Plasminogen activator inhibitor type 1 (PAI 1); Serine proteinase; Serpin; Urokinase type plasminogen activator (uPA)

Indexed keywords

ENZYME PRECURSOR; ESTER DERIVATIVE; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEINASE; SERINE PROTEINASE INHIBITOR; SUBTILISIN; TRYPSIN; UROKINASE;

AMINO ACID SEQUENCE; ARTICLE; CATALYSIS; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME CONFORMATION; ENZYME INHIBITION; ENZYME MECHANISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INHIBITION KINETICS; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; STEREORADIOGRAPHY;

AMINO ACID SEQUENCE; AMINO ACIDS; ANIMALS; ANIONS; BINDING SITES; CATALYTIC DOMAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISULFIDES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENDOPEPTIDASES; HUMANS; HYDROLYSIS; IMMUNOGLOBULIN G; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDES; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, CELL SURFACE; SEQUENCE ANALYSIS, PROTEIN; SERINE ENDOPEPTIDASES; SERPINS; SUBTILISIN; TIME FACTORS; TRYPSIN;

EID: 0034832458     PISSN: 00142956     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1432-1327.2001.01921.x     Document Type: Article

References (51)

1. 1-antitrypsin for structure and function of serpins
2. What do dysfunctional serpins tell us about molecular mobility and disease?
3. The biostructural pathology of the serpins: Critical function of sheet opening mechanism
4. Divining the serpin inhibition mechanism: A suicide substrate `spring'?
5. Structure-function relationships in serpins: Current concepts and controversies
6. Serpin-protease complexes are trapped as stable acyl-enzyme intermediates
7. A fluorescent probe study of plasminogen activator inhibitor-1. Evidence for reactive center loop insertion and its role in the inhibitory mechanism
8. Major proteinase movement upon stable serpin-proteinase complex formation
9. 1-proteinase inhibitor Pittsburgh
10. Formation of the covalent serpin-proteinase complex involves translocation of the proteinase by more than 70 Å and full insertion of the reactive center loop into β-sheet A
11. The inhibition mechanism of serpins. Evidence that the mobile reactive center loop is cleaved in the native protease-inhibitor complex
12. Structural insights into serpin-protease complexes reveal the inhibitory mechanism of serpins
13. An ester bond linking a fragment of a serine proteinase to its serpin inhibitor
14. The structure of a serpin-protease complex revealed by intramolecular distance measurements using donor-donor energy migration and mapping of interaction sites
15. 1-proteinase inhibitor
16. Routes of thrombin action in the production of proteolytically modified, secondary forms of antithrombin-thrombin complex
17. 1-antichymotrypsin as seen by enhanced sensitivity to proteolysis
18. 1-proteinase inhibitor has an increased structural flexibility
19. Distortion of the active site of chymotrypsin complexed with a serpin
20. Effects of serpin binding on the target proteinase: Global stabilization, localized increased structural flexibility, and conserved hydrogen bonding at the active site
21. 1-proteinase inhibitor complexed forms
22. Plasminogen activator inhibitors: Hormonally regulated serpins
23. The urokinase-type plasminogen activator system in cancer metastasis: A review
24. The plasminogen activation system in tumor growth, invasion, and metastasis
25. 2-macroglobulin receptor in human breast carcinomas
26. Type-1 plasminogen-activator inhibitor: Conformational differences between latent, active, reactive-centre-cleaved and plasminogen-activator-complexed forms, as probed by proteolytic susceptibility
27. Type-1 inhibitor of plasminogen activators. Distinction between latent, activated and reactive centre-cleaved forms with thermal stability and monoclonal antibodies
28. Inter-conversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor
29. Tissue-type plasminogen activator: Variants and crystal/solution structures demarcate structural determinants of function
30. The complete amino acid sequence of low molecular mass urokinase from human urine
31. Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody
32. Affinity purification of active plasminogen activator inhibitor-1 (PAI-1) using immobilized anhydrourokinase. Demonstration of the binding, stabilization, and activation of PAI-1 by vitronectin
33. Lysosomal degradation of receptor-bound urokinase-type plasminogen activator is enhanced by its inhibitors in human trophoblastic choriocarcinoma cells
34. Cleavage of structural proteins during the assembly of the head of bacteriophage T4
35. Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1 to 100 kDa
36. Analysis of protein and peptide mixtures: Evaluation of three sodium dodecyl sulphate-polyacrylamide gel electrophoresis buffer systems
37. Blue native electrophoresis for isolation of membrane protein complexes in enzymatically active form
38. SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling
39. The crystal structure of the catalytic domain of human urokinase-type plasminogen activator
40. Modeling studies of the change in conformation required for cleavage of limited proteolytic sites
41. Probing the partly folded states of proteins by limited proteolysis
42. The three-dimensional structure of Asp189Ser trypsin provides evidence for an inherent structural plasticity of the protease
43. Structure-function studies of the SERPIN plasminogen activator inhibitor type 1. Analysis of chimeric strained loop mutants
44. Structural basis of the activation and action of trypsin
45. Bovine chymotrypsinogen A X-ray crystal structure analysis and refinement of a new crystal form at 1.8 Å resolution
46. The isomorphous structures of prethrombin2, hirugen-, and PPACK-thrombin: Changes accompanying activation and exosite binding to thrombin
47. The co-crystal structure of unliganded bovine α-thrombin and prethrombin-2: Movement of the Tyr-Pro-Pro-Trp segment and active site residues upon ligand binding
48. Lysine 156 promotes the anomalous proenzyme activity of tPA: X-ray crystal structure of single-chain human tPA
49. Structural basis of profactor D activation: From a highly flexible zymogen to a novel self-inhibited serine protease, complement factor D
50. Crystal structure of the proenzyme domain of plasminogen
51. Human plasminogen catalytic domain undergoes an unusual conformational change upon activation